Are Automation and AI the Future of Brain Scan Analysis?

After decades of development work, and trial and error and money spent, you might think that by the time your head is put inside a magnetic resonance imaging (MRI) scanner at a hospital, the difficult part of looking inside the brain is finished. But often it’s the analysis that comes after you leave the scanner that proves most challenging for physicians. The error rate for image analysis remains alarmingly high, and radiologists are being asked to handle and process larger numbers of scans every year. Can automation lend a hand? We talked to Dr. Chris Airriess, CEO at CorTechs Labs Inc., which has developed a post-processing scan software called NeuroQuant designed to streamline the analysis pipeline. We asked Chris about the current challenges in analysis, what datasets NeuroQuant would be trained on, and whether the general public will trust their medical scans to an AI.

Spotlight

Amagen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

OTHER ARTICLES
Research

Immunology: A New Frontier in Medical Science

Article | July 11, 2022

Introduction Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders. Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities. Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices. Accelerating Investments: Paving the Way for Immunology The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments. Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments. For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science. These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. The Way Forward Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases. With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space. Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Read More
MedTech

Laboratory Information Management System for Biotech Labs: Significance & Benefits

Article | July 16, 2022

If you have ever visited the testing laboratory of a large biotechnology company, you will be aware that managing the laboratory's operations single-handedly is no easy task. The greater the size of a lab, the more research and testing activities it must accommodate. A variety of diagnostic tests are prescribed for patients in order to detect various diseases. For example, it may include blood glucose testing for diabetics, lipid panel, or liver panel tests for evaluating cardiac risk and liver function, cultures for diagnosing infections, thyroid function tests, and others. Laboratory management solutions such as laboratory information management systems (LIMS) and other software play a significant role in managing various operational data at biotech laboratories. It is one of the important types of software developed to address thedata management and regulatory challenges of laboratories. The software enhances the operational efficiency of biotech labs by streamlining workflows, proper record-keeping, and eradicating the need for manually maintaining data. What Are the Benefits of Laboratory Information Management Software in Biotechnology? As the trends of digitization and technology continue to create deeper inroads into the biotechnology sector, a significant rise in the adoption of innovative medical software solutions, such as LIMS, is being witnessed for managing research data, testing reports, and post-research results globally. Here are a few reasons that are encouraging biotech facilities to adopt LIMS solutions Real-Time Data Collection and Tracking Previously, collecting and transporting samples was a tedious and time-consuming task. However, the adoption of LIMS with innovative tracking modules has made the job easier. The real-time sample tracking feature of LIMS has made it possible for personnel to collect the research data in real-time and manage and control the workflow with a few mouse clicks on the screen. Increase Revenue LIMS makes it possible to test workflows while giving users complete control over the testing process. A laboratory is able to collect data, schedule equipment maintenance or upgrades, enhance operational efficiency, and maintain a lower overhead with the help of the LIMS, thereby increasing revenue. Streamlined Workflow With its completion monitoring, LIMS speeds up laboratory workflows and keeps track of information. It assigns tasks to the specialist along with keeping a real-time track of the status and completion of each task. LIMS is integrated into the laboratory using lab information, which ultimately speeds up internal processes and streamlines the workflow. Automatic Data Exchange LIMS solutions store data in a centralized database. Automated transfer of data between departments and organizations is one of the major features of LIMS. Through its automated information exchange feature, LIMS improves internal operations, decreases the reporting time for data sharing, and assists in faster decision-making. Final Thoughts As the healthcare sector continues to ride the wave of digital transformation, biotech laboratories are emphasizing adopting newer technologies to keep up with the changes. Citing this trend, laboratory information management systems are becoming crucial for biotech and medical organizations for maintaining research data, instant reporting, and managing confidential, inventory, and financial data with centralized data storage.

Read More
Medical

5 Biotech Stocks Winning the Coronavirus Race

Article | July 14, 2022

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More
Medical

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Spotlight

Amagen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Related News

Neurocrine Biosciences and Xenon Launch Up-to-$1.7B Epilepsy, Neuroscience Collaboration

GEN | December 02, 2019

Neurocrine Biosciences has agreed to exclusively license and co-develop Xenon Pharmaceuticals’ Phase I epilepsy candidate XEN901 as a treatment for children—as well as develop three preclinical compounds, the companies said today—through a collaboration that could generate up to $1.7 billion for Xenon. XEN901 is designed as a highly selective Nav1.6 sodium channel inhibitor being developed to treat children with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy. Xenon has completed a Phase I trial of a powder-in-capsule formulation of XEN901 in healthy adults. However, Xenon has also developed a pediatric-specific, granule formulation of XEN901, and has completed juvenile toxicology studies intended to support pediatric development of the drug candidate. “With its proven expertise in developing and commercializing treatments for neurological disorders, we believe Neurocrine Biosciences is an ideal partner to maximize the potential value of XEN901 for patients,” Xenon CEO Simon Pimstone, MD, PhD, FRCPC, said in a statement.

Read More

Machine Learning Harnessed To Build Map of the Connectome

Technology Networks | November 08, 2019

The brain is considered to be one of the most complex systems in existence. And while significant headway has been made to understand it, we tend to generate more questions than answers. But now a research team led by Kyoto University has developed a machine learning model that allows scientists to reconstruct neuronal circuitry by measuring signals from the neurons themselves. The model has the potential to elucidate the difference in neuronal computation in different brain regions. To comprehend the brain, we must look at the neurons that construct it. Our entire world of perception runs across these billions of cells in our head. And that is compounded by the exponentially larger number of connections -- known as synapses -- between them, making the path to our understanding a challenge. Shigeru Shinomoto from Kyoto University's School of Science, who headed the project, explains that although it is possible to record the activity of individual neurons in the brain -- and that number has increased dramatically over the last decade -- it is still a challenge to map out how each of these cells connects to each other.

Read More

UK Scientists Speed up Brain Cancer Diagnosis with AI

Labiotech.eu | November 05, 2019

A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people suspected of having brain tumors. The researchers used an existing technique called infrared spectroscopy to screen 20,000 chemicals in their blood, and then used AI to identify the chemicals that signal a brain tumor. The test correctly identified 82% of the patients that would go on to be diagnosed with brain cancer. Patients flagged with this brain cancer test can be prioritized for confirmatory brain scans, and their diagnosis might take just two weeks. In current practice, it’s difficult to diagnose tumors from patients’ symptoms, and the process can take up to two months, with multiple visits to the doctor. The blood test is being developed by Brennan’s collaborator, the UK company ClinSpec Diagnostics. While other groups are working on cancer tests using infrared spectroscopy and AI, ClinSpec’s test is the most advanced, according to Brennan.

Read More

Neurocrine Biosciences and Xenon Launch Up-to-$1.7B Epilepsy, Neuroscience Collaboration

GEN | December 02, 2019

Neurocrine Biosciences has agreed to exclusively license and co-develop Xenon Pharmaceuticals’ Phase I epilepsy candidate XEN901 as a treatment for children—as well as develop three preclinical compounds, the companies said today—through a collaboration that could generate up to $1.7 billion for Xenon. XEN901 is designed as a highly selective Nav1.6 sodium channel inhibitor being developed to treat children with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy. Xenon has completed a Phase I trial of a powder-in-capsule formulation of XEN901 in healthy adults. However, Xenon has also developed a pediatric-specific, granule formulation of XEN901, and has completed juvenile toxicology studies intended to support pediatric development of the drug candidate. “With its proven expertise in developing and commercializing treatments for neurological disorders, we believe Neurocrine Biosciences is an ideal partner to maximize the potential value of XEN901 for patients,” Xenon CEO Simon Pimstone, MD, PhD, FRCPC, said in a statement.

Read More

Machine Learning Harnessed To Build Map of the Connectome

Technology Networks | November 08, 2019

The brain is considered to be one of the most complex systems in existence. And while significant headway has been made to understand it, we tend to generate more questions than answers. But now a research team led by Kyoto University has developed a machine learning model that allows scientists to reconstruct neuronal circuitry by measuring signals from the neurons themselves. The model has the potential to elucidate the difference in neuronal computation in different brain regions. To comprehend the brain, we must look at the neurons that construct it. Our entire world of perception runs across these billions of cells in our head. And that is compounded by the exponentially larger number of connections -- known as synapses -- between them, making the path to our understanding a challenge. Shigeru Shinomoto from Kyoto University's School of Science, who headed the project, explains that although it is possible to record the activity of individual neurons in the brain -- and that number has increased dramatically over the last decade -- it is still a challenge to map out how each of these cells connects to each other.

Read More

UK Scientists Speed up Brain Cancer Diagnosis with AI

Labiotech.eu | November 05, 2019

A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people suspected of having brain tumors. The researchers used an existing technique called infrared spectroscopy to screen 20,000 chemicals in their blood, and then used AI to identify the chemicals that signal a brain tumor. The test correctly identified 82% of the patients that would go on to be diagnosed with brain cancer. Patients flagged with this brain cancer test can be prioritized for confirmatory brain scans, and their diagnosis might take just two weeks. In current practice, it’s difficult to diagnose tumors from patients’ symptoms, and the process can take up to two months, with multiple visits to the doctor. The blood test is being developed by Brennan’s collaborator, the UK company ClinSpec Diagnostics. While other groups are working on cancer tests using infrared spectroscopy and AI, ClinSpec’s test is the most advanced, according to Brennan.

Read More

Events